基于癌症基因组图集数据库分析锌指蛋白580 mRNA在肝细胞癌中的表达及意义

毛骏; 李仁礼; 李海; 夏时海; 张文成; 向晓辉

doi:10.3969/j.issn.1001-5256.2019.10.020

基于癌症基因组图集数据库分析锌指蛋白580 mRNA在肝细胞癌中的表达及意义

DOI: 10.3969/j.issn.1001-5256.2019.10.020

1. 武警后勤学院
2. 武警特色医学中心消化病科
3. 天津市肝脏胰腺纤维化与分子诊疗重点实验室

基金项目:

天津市自然科学基金(17JCYBJC26700)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1186
- HTML全文浏览量: 31
- PDF下载量: 250
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-01
- 出版日期: 2019-10-20

Expression and clinical significance of ZNF580 mRNA in hepatocellular carcinoma: An analysis based on The Cancer Genome Atlas database

The Affiliated Tumor Hospital of Guangxi Medical University

Research funding:

摘要

摘要:
目的研究锌指蛋白580（ZNF580） mRNA在肝细胞癌中的表达以及临床价值,预测ZNF580 mRNA在肝细胞癌发生发展中的作用。方法从癌症基因组图集（TCGA）数据库下载肝细胞癌数据集,获得ZNF580 mRNA基因表达谱和临床信息。利用相关生物信息学方法,分析ZNF580 mRNA在肝细胞癌中表达的情况与临床病理指标的相关性以及对预后的影响。用基因富集化分析预测ZNF580 mRNA在肝细胞癌中调控的可能通路。计量资料2组间比较采用t检验,计数资料组间比较采用χ2检验,并运用Cox比例风险回归模型分析影响患者预后的危险因素,计算风险比（HR）及95%可信区间（95%CI）。结果在TCGA数据库中,ZNF580 mRNA的表达水平在肝癌组织中明显高于癌旁组织（8. 440±0. 705 vs 7. 736±0. 387,P<0. 05）,其表达水平在不同肿瘤分级的患者中差异有统计学意义（t=-2. 068,P <0. 05）。ZNF580 mRNA高表达患者的总体生存期明显低于ZNF580 mRNA低表达患者（χ2=5. 456,P <0. 05）。多因素Co...
- 癌,肝细胞 /
- 锌指蛋白580 mRNA /
- 计算生物学 /
- 危险因素
Abstract:
Objective To establish and validate a nomogram for overall survival(OS) of patients after hepatectomy for hepatocellular carcinoma(HCC). Methods A retrospective analysis was performed for the clinical data of 1013 patients who underwent hepatectomy for HCC in The Affiliated Tumor Hospital of Guangxi Medical University from February 2004 to October 2013. These patients were randomly divided into training cohort with 710 patients and validation cohort with 303 patients. For the training cohort,the Cox proportional hazards model was used to determine independent risk factors and a nomogram was established to predict 1-,3-,and 5-year survival rates. The performance of this nomogram was evaluated by internal verification within the training cohort and external verification of the validation cohort,as well as C-index,receiver operating characteristic(ROC) curve,and calibration curve. The independent samples t-test was used for comparison of continuous variables between groups,and the chi-square test or the Fisher's exact test was used for comparison of categorical variables between groups. The Cox proportional hazards model was used for univariate and multivariate analyses. Results The 1-,3-,and 5-year OS rates in the training cohort were 0. 72,0. 48,and 0. 34,respectively,and those in the validation cohort were 0. 66,0. 45,0. 32,respectively. The univariate and multivariate analyses showed that age,number of tumors,tumor diameter,tumor capsule,vascular invasion,microsatellite lesion,aspartate aminotransferase(AST),and alpha-fetoprotein(AFP) were the influencing factors for OS in patients after hepatectomy for HCC(all P < 0. 05),and such factors were used to establish a nomogram model. In the training cohort,the C-index for predicting OS was 0. 748(95% confidence interval [CI]: 0. 712-0. 784); the calibration curve of 1-,3-,and 5-year survival rates showed that the predicted value of the nomogram was in good consistency with the actual values observed; this nomogram model had an area under the ROC curve of 0. 81(95% CI: 0. 76-0. 87),0. 82(95% CI: 0. 77-0. 88),and 0. 79(95% CI: 0. 71-0. 88),respectively,in predicting the 1-,3-,and 5-year survival rates. In the validation cohort,the C-index was 0. 712(95% CI: 0. 685-0. 739); the calibration curve of 1-,3-,and 5-year survival rates showed that the predicted value of the nomogram was in good consistency with the actual values observed; this nomogram model had an area under the ROC curve of 0. 75(95% CI: 0. 71-0. 79),0. 77(95%CI: 0. 73-0. 81),and 0. 74(95% CI: 0. 68-0. 80),respectively,in predicting the 1-,3-,and 5-year survival rates. Conclusion The nomogram established in this study can effectively predict OS in patients after hepatectomy for HCC.
- carcinoma,hepatocellular /
- prognosis /
- nomogram /
- risk factors

HTML全文

参考文献(22)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] TABRIZIAN P,JIBARA G,SHRAGER B,et al. Recurrence of hepatocellular cancer after resection[J]. Ann Surg,2015,261(5):947-955.

[3] POON R,FAN S,LO C,et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function-Implications for a strategy of salvage transplantation[J]. Ann Surg,2002,235(3):373-382.

[4] LIAO R,FU YP,WANG T,et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:A retrospective cohort study at two centers in China[J]. Oncotarget,2017,8(1):1774-1787.

[5] XIAO Z,YAN Y,ZHOU Q,et al. Development and external validation of prognostic nomograms in hepatocellular carcinoma patients:A population based study[J]. Cancer Manag Res,2019,11:2691-2708.

[6] PANG Q,ZHOU L,QU K,et al. Validation of inflammationbased prognostic models in patients with hepatitis B-associated hepatocellular carcinoma:A retrospective observational study[J]. Eur J Gastroenterol Hepatol,2018,30(1):60-70.

[7] CAI BB,SHI KQ,LI P,et al. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection[J]. Clin Chim Acta,2018,485:187-194.

[8] YU C,ZHANG Y. Development and validation of a prognostic nomogram for early-onset colon cancer[J]. Biosci Rep,2019,39(6). pii:BSR20181781.

[9] DENG W,ZHANG W,YANG J,et al. Nomogram to predict overall survival for thoracic esophageal squamous cell carcinoma patients after radical esophagectomy[J]. Ann Surg Oncol,2019,26(9):2890-2898.

[10] SHI HT,JIANG YQ,CAO HG,et al. Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients[J]. Dis Markers,2018,2018:1787424.

[11] MAI RY,YE JZ,WANG YY,et al. Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J]. J Clin Hepatol,2018,34(2):292-297.(in Chinese)麦荣云,叶甲舟,王言焱,等. ALBI联合APRI对HBV相关肝细胞癌肝切除术后肝衰竭发生的预测价值[J].临床肝胆病杂志,2018,34(2):292-297.

[12] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.

[13] SHEN J,HE L,LI C,et al. Prognostic nomograms for patients with resectable hepatocelluar carcinoma incorporating systemic inflammation and tumor characteristics[J]. Oncotarget,2016,7(49):80783-80793.

[14] McGLYNN KA,PETRICK JL,LONDON WT. Global epidemiology of hepatocellular carcinoma[J]. Clin Liver Dis,2015,19(2):223-238.

[15] HSU CY,LIU PH,HSIA CY,et al. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma[J]. Liver Int,2016,36(10):1498-1506.

[16] ZHANG XP,CHEN ZH,ZHOU TF,et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection:A large-scale,multicenter study[J]. Eur J Surg Oncol,2019,45(9):1644-1651.

[17] WANG Y,SUN K,SHEN J,et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy[J].Cancer Res Treat,2019.[Epub ahead of print]

[18] CILLO U,VITALE A,GRIGOLETTO F,et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system[J]. J Hepatol,2006,44(4):723-731.

[19] GUGLIELMI A,RUZZENENTE A,PACHERA S,et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response[J]. Am J Gastroenterol,2008,103(3):597-604.

[20] GRIECO A,POMPILI M,CAMINITI G,et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:Comparison of Okuda,CLIP,and BCLC staging systems in a single Italian centre[J]. Gut,2005,54(3):411-418.

[21] LIAO R,PENG C,LI M,et al. Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy[J].Cancer Med,2018,7(4):1170-1182.

[22] SHIM JH,JUN MJ,HAN S,et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma[J]. Ann Surg,2015,261(5):939-946.

施引文献

资源附件(0)

访问统计